Forging a position as an innovative player in
infectious disease vaccines and therapies
Load more...

CEO AGM 2023 Presentation

November 30, 2023

View the CEO AGM 2023 Presentation

Read More

BioDiem Results of Annual General Meeting

November 30, 2023

To view the BioDiem Results of Annual General Meeting read the PDF here

Read More

2023 AGM Notice of Meeting

November 9, 2023

2023 BioDiem Notice of AGM

Read More

2023 BioDiem Annual Report

November 9, 2023

BioDiem Annual Report 2023

Read More

Opal capital raise for growth strategy – Information Memorandum

September 1, 2023

Melbourne, 1 September 2023: Opal Biosciences Limited (“Opal”) today announced its Information Memorandum to raise up to $2.5 million through the issue of 10,000,000 new Shares at $0.25 (25 cents) per share together with one (1) free attaching Option for every one (1) new Share having an exercise price of $0.25 (25 cents) and expiring […]

Read More

BioDiem Ltd Board change

August 9, 2023

Melbourne, 9 August 2023: Infectious disease therapy and vaccine development company BioDiem Ltd today announced a change to its board of directors with the retirement of Mr Fergus Mak Po Kan who joined the BioDiem board in September 2021. BioDiem’s chairman Mr Damien Hannes said “We would like to express the company’s gratitude for the […]

Read More

Company Update and EOFY 2023 Information

August 4, 2023

Company Update and EOFY 2023 Information  Melbourne, 4 Aug 2023: Australian vaccine development company BioDiem Ltd today and its subsidiary company Opal Biosciences Ltd (“Opal”) are pleased to provide the following update. Live attenuated flu virus (LAIV)  vaccine China-based Changchun BCHT Biotechnology Co (BCHT) holds an exclusive licence from BioDiem for the vaccine technology based […]

Read More

Opal Biosciences awarded Investment Attraction Fund grant by WA government

July 18, 2023

Opal Biosciences awarded Investment Attraction Fund grant by WA government Melbourne, 18 July 2023: Australian pharmaceutical development company Opal Biosciences Limited (“Opal”) is pleased to announce it has been awarded an Investment Attraction Fund grant of $5m by the Government of Western Australia (WA). The grant will support establishment of a manufacturing facility in Perth […]

Read More

Proposed acquisition: Formulytica

June 21, 2023

Proposed acquisition of specialist formulation company Formulytica Melbourne, 21 June 2023: Opal Biosciences Limited (“Opal”) is pleased to announce its proposed merger with specialist company, Formulytica Pty Ltd (“Formulytica”).  Opal and Formulytica have partnered to establish a new sterile pharmaceutical development and manufacturing facility. The new facility will be focused on small scale product manufacture […]

Read More

2022 BioDiem AGM

December 21, 2022

BioDiem 2022 AGM Results of AGM CEO Presentation Chairman’s Address 

Read More

2022 BioDiem Annual Report

November 25, 2022

View the Annual Report

Read More

Exercise of Options

October 1, 2022

Read the announcement 

Read More

EOFY 2022 Information

August 11, 2022

EOFY 2022 Information

Read More

BioDiem Board Change

May 4, 2022

BioDiem Board change

Read More

BioDiem Board Changes

March 29, 2022

Read the full announcement

Read More

New BioDiem Board Appointment

February 25, 2022

Read the full announcement

Read More

2021 AGM

November 30, 2021

2021 AGM Results of Meeting 2021 AGM Chairman’s Address 2021 AGM Presentation

Read More

Notice of Meeting

November 8, 2021

Notice of Meeting

Read More

2021 BioDiem Annual Report

November 4, 2021

2021 Annual report

Read More

EOFY 2021 Information

September 22, 2021

Highlights: • LAIV flu vaccine royalty receipt • Progress in Opal’s bid to secure lease to GSK Boronia manufacturing plant • EOFY 2021 share price information Read the full annoucement

Read More

Board changes

September 8, 2021

Announcement of Board Changes

Read More

Biotech Precinct Progress

July 14, 2021

Biotech Precinct Progress

Read More

LAIV Success in China

June 30, 2021

LAIV Success in China – Read announcement

Read More

Opal acquisition of Formulytica – Capital raising

May 6, 2021

Opal acquisition of Formulytica – Capital raising         

Read More

Opal Biosciences 2021 Information Memorandum

May 6, 2021

Opal Biosciences 2021 Information Memorandum

Read More

Opal announces acquisition of specialist formulation company Formulytica

May 5, 2021

Opal announces acquisition of specialist formulation company Formulytica 

Read More

BioDiem Half Year Announcement

April 1, 2021

Half Year Results Announcement

Read More

BioDiem Half Year Report

April 1, 2021

BioDiem Half Year Report  

Read More

2020 AGM Results of Meeting

December 1, 2020

2020 AGM Results of Meeting

Read More

2020 AGM Chairman’s Address

December 1, 2020

2020 AGM Chairman’s Address

Read More

2020 AGM Presentation

December 1, 2020

2020 AGM Presentation

Read More

2020 Annual Report

October 30, 2020

BioDiem Annual Report 2020 Notice of Annual General Meeting – Explanatory Statement and Proxy Form

Read More

Launch of LAIV Flu vaccine in China

August 25, 2020

Launch of LAIV Flu vaccine in China Melbourne, 25 August 2020:  Australian vaccine development company BioDiem Ltd is pleased to announce the product launch of Changchun BCHT Biotechnology Co (BCHT)’s LAIV vaccine in China. This is a major milestone for BCHT and for BioDiem. BCHT is BioDiem’s licencee for the LAIV flu vaccine technology in […]

Read More

BioDiem Update and EOFY information

July 7, 2020

BioDiem_OPAL Update and EOFY information

Read More

BioDiem Releases Half Year Results

March 27, 2020

BioDiem Releases Half Year Results Half-year Financial Report

Read More

2020 LAIV Influenza Vaccine Approved in China

February 28, 2020

Read the announcement: LAIV Influenza Vaccine Approved in China Melbourne  

Read More

2019 AGM CEO Presentation, Chaiman’s Address, Results

November 29, 2019

AGM Results Chaiman’s Address 2019 AGM Presentation

Read More

2019 Notice of Meeting and Proxy Form

October 29, 2019

BioDiem 2019 AGM Notice of Meeting and Proxy Form

Read More

2019 Annual Report

October 28, 2019

BioDiem Annual Report 2019

Read More

Company Update and EOFY 2019 Information

July 12, 2019

Company Update and EOFY 2019 Information

Read More

BioDiem Releases Half Year Results

March 20, 2019

BioDiem Half Year Results – 31 December 2018

Read More

BioDiem Half-year Financial Report – 31 December 2018

March 20, 2019

Half-year Financial Report – 31 December 2018

Read More

BioDiem 2018 AGM Chairman’s address

November 27, 2018

BioDiem 2018 AGM Chairman’s address

Read More

BioDiem CEO Presentation 2018 AGM

November 27, 2018

BioDiem CEO Presentation 2018 AGM

Read More

BioDiem AGM 2018 Results of Meeting

November 27, 2018

BioDiem AGM 2018 Results of Meeting

Read More

2018 BioDiem Annual Report and Notice of Annual General Meeting and Explanatory Statement and Proxy Form

November 8, 2018

2018 BioDiem Annual Report Notice of Annual General Meeting and Explanatory Statement and Proxy Form

Read More

Company Update and EOFY 2018 Information

August 3, 2018

Infectious disease therapy and vaccine development company BioDiem Ltd and its subsidiary company Opal Biosciences Ltd (“Opal”) are pleased to provide the following information.

Read More

Opal Information Memorandum Announcement

July 25, 2018

Opal Biosciences Limited announces its Information Memorandum

Read More

BioDiem receives Innovation Connections grant for Opal work

May 1, 2018

BioDiem receives Innovation Connections grant for Opal work

Read More

Opal BioSciences – Half-year Results & Financial Report

April 9, 2018

Opal BioSciences – Half-year Results Opal Biosciences Limited – Half-year Financial Report 31 Dec 2017

Read More

BioDiem Half Year Results & Financial Report

April 9, 2018

BioDiem Limited – Half-year Financial Report 31 Dec 2017 BioDiem Limited – Half-year Results

Read More

2018 Opal: Completion of Placement and Board change

March 5, 2018

Read the full announcement: Opal: Completion of Placement and Board change      

Read More

2018 Patent grant in US and Europe

February 16, 2018

Read the full announcement: Scedosporium patent grant in US and Europe

Read More

2017 BioDiem AGM CEO Presentation

November 21, 2017

2017 BioDiem AGM CEO Presentation

Read More

Results of 2017 BioDiem AGM

November 21, 2017

Results of BioDiem 2017 AGM

Read More

2017 BioDiem AGM Chairman’s address

November 21, 2017

2017 BioDiem AGM Chairman’s address

Read More

Receipt of 2017 Income Tax Return Refund

November 10, 2017

Receipt of 2017 Income Tax Return Refund

Read More

2017 Notice of Annual General Meeting Explanatory Statement

October 22, 2017

2017 Notice of Annual General Meeting – Explanatory Statement

Read More

2017 BioDiem Annual Report

October 21, 2017

  2017 BioDiem Annual Report

Read More

BioDiem- OPAL Update and EOFY Information

July 10, 2017

BioDiem_OPAL Update and EOFY information

Read More

Receipt of 2016 Income Tax Return Refund

May 22, 2017

20170522 Receipt of 2016 Income Tax Return Refund (BioDiem)

Read More

BioDiem Releases Half Year Results

March 17, 2017

BioDiem Releases Half Year Results

Read More

2016 Chairman’s Address

October 19, 2016

2016 Chairman’s Address

Read More

2016 BioDiem Results of Meeting

October 19, 2016

2016 BioDiem Results of Meeting

Read More

Opal Biosciences Annual Report and Notice of Meeting 2016 now available

October 4, 2016

Opal Biosciences Annual Report 2016 Opal Biosciences Notice of Meeting and proxy form 2016 For more information, visit www.opalbiosciences.com

Read More

BioDiem Notice of Annual General Meeting and Proxy form 2016

September 19, 2016

BioDiem Notice of Annual General Meeting and Proxy form 2016

Read More

BioDiem Annual Report 2016

September 19, 2016

BioDiem Annual Report 2016

Read More

Completion of Entitlement Offer and Issue of Convertible Preference Shares

August 10, 2016

Completion of Entitlement Offer and Issue of Convertible Preference Shares

Read More

Non-renounceable pro rata Entitlement Offer

June 14, 2016

Non-renounceable pro rata Entitlement Offer

Read More

BioDiem Entitlement Offer Replacement Prospectus

June 14, 2016

ENTITLEMENT OFFER REPLACEMENT PROSPECTUS   By accessing the BioDiem Limited Entitlement Offer Prospectus contained on this website (a copy of which has been lodged with ASIC), you must acknowledge the following terms and agree to be bound by them: A copy of this Prospectus was lodged with ASIC on 6 June 2016. Neither ASIC nor […]

Read More

Results of General Meeting

May 11, 2016

Results of General Meeting

Read More

BDM-I Presentation at European Clinical Conference

April 13, 2016

BDM-I Presentation at European Clinical Conference

Read More

Notice of General Meeting with Proxy

April 8, 2016

Notice of General Meeting with Proxy

Read More

Influenza Vaccine Clinical Trial commences in China

March 31, 2016

Influenza Vaccine Clinical Trial commences in China

Read More

BioDiem Releases Half Year Results

March 31, 2016

BioDiem Releases Half Year Results

Read More

BioDiem/Opal Biosciences Investor presentation at Wholesale Investor

February 26, 2016

BioDiem/Opal Biosciences Investor presentation at Wholesale Investor

Read More

Share Trading Contact Information

January 22, 2016

Share Trading Contact Information

Read More

Completion of Non-renounceable Entitlement Offer and Issue of Entitlement and Shortfall Shares

January 22, 2016

Completion of Non-renounceable Entitlement Offer and Issue of Entitlement and Shortfall Shares

Read More

Appointment of Prof Li to the BioDiem Board

January 22, 2016

Appointment of Prof Li to the BioDiem board

Read More

Receipt of 2015 Income Tax Return Refund

December 23, 2015

Receipt of 2015 Income Tax Return Refund (BioDiem) – (FINAL)

Read More

Rights Issue Closure and Results

December 22, 2015

Rights Issue Closure and Results Announcement – (FINAL)

Read More

Further US patent granted for Opal

December 11, 2015

Further US patent granted for Opal

Read More

BioDiem is presented at Wholesale Investor, Sydney

December 4, 2015

BioDiem is presented at Wholesale Investor, Sydney

Read More

BioDiem Rights Issue

November 27, 2015

BioDiem Rights Issue  and BioDiem Entitlement Offer Prospectus

Read More

BioDiem is presented at Wholesale Investor, Melbourne

November 25, 2015

BioDiem is presented at Wholesale Investor, Melbourne

Read More

BioDiem Entitlement Offer Prospectus

November 18, 2015

ENTITLEMENT OFFER PROSPECTUS By accessing the BioDiem Limited Entitlement Offer Prospectus contained on this website (a copy of which has been lodged with ASIC), you must acknowledge the following terms and agree to be bound by them: A copy of this Prospectus was lodged with ASIC on 17 November 2015. Neither ASIC nor its officers […]

Read More

New European patents for Opal Biosciences antimicrobial, BDM-I

November 6, 2015

New European patents for Opal Biosciences antimicrobial, BDM-I

Read More

Nasovac-S WHO PreQualification certification

October 21, 2015

NasovacS WHO PreQualification certification

Read More

AGM 2015 Presentation

October 20, 2015

AGM 2015 Presentation FINAL

Read More

2015 AGM CEO Address

October 20, 2015

CEO Address AGM 2015

Read More

Chairman’s Address AGM 2015

October 19, 2015

Chairman’s address AGM 2015

Read More

2015 Results of Meeting

October 19, 2015

2015 Results of Meeting

Read More

Chinese FDA gives approval to start LAIV vaccine clinical trials

September 24, 2015

Chinese FDA gives approval to start LAIV vaccine clinical trials    

Read More

BioDiem Notice of Annual General Meeting and Proxy form 2015

September 17, 2015

BioDiem Notice of Annual General Meeting and Proxy form 2015

Read More

BioDiem 2015 Annual Report

September 17, 2015

BioDiem 2015 Annual report

Read More

Opal Update

August 26, 2015

Opal Update

Read More

Shareholder Update

August 7, 2015

Shareholder Update

Read More

July 20, 2015

Opal Biosciences CEO Interview, Wholesale Investor

Read More

Opal’s technology presented at the Australian Society for Microbiology Annual Meeting

July 16, 2015

Opal’s technology presented at the Australian Society for Microbiology Annual Meeting

Read More

Opal Biosciences article in The Australian newspaper 13th July 2015

July 13, 2015

Opal Biosciences article in The Australian newspaper 13th July 2015

Read More

Successful grant for BDM-I – Griffith University

July 10, 2015

Successful grant for BDM-I – Griffith University

Read More

Opal Biosciences Investor Briefing, Melbourne 14 July 2015

July 7, 2015

Opal Biosciences Investor Briefing, Melbourne 14 July 2015

Read More

Opal Biosciences Investor Briefing, Sydney 13 July 2015

July 7, 2015

Opal Biosciences Investor Briefing, Sydney 13 July 2015

Read More

Results of General Meeting

July 7, 2015

Results of General Meeting

Read More

Opal Biosciences’ anti-infective technology profiled at 2015 BIO International Convention

June 17, 2015

Opal Biociences’ anti-infective technology profiled at 2015 Bio International Convention

Read More

BioDiem Shareholder Update: Opal Biosciences Ltd.

June 5, 2015

Shareholder Update; Opal Biosciences

Read More

May 2015 Shareholder Update

May 14, 2015

May 2015 Shareholder Update

Read More

Board Announcement – Don Brooks

March 24, 2015

Board Announcement – Don Brooks

Read More

BioDiem Half Year Financial report

March 16, 2015

BioDiem Half Year Financial report

Read More

Notification of Exercise of Options

February 23, 2015

Notification of Exercise of Options

Read More

Notice of extension of exercise period for BioDiem options to 13th February 2015

January 6, 2015

Notice of extension of exercise period for BioDiem options to 13th February 2015

Read More

Extension of BDM option exercise closing date

December 30, 2014

Extension of BDM option exercise closing date

Read More

New Japanese patent for antimicrobial BDM-I

December 24, 2014

New Japanese patent for antimicrobial BDM-I

Read More

Professor Arthur Li directorship

December 24, 2014

Professor Arthur Li directorship

Read More

Wholesale Investor’s Sydney Capital Showcase and Australia Biotech Invest, Melbourne

December 5, 2014

Wholesale Investor’s Sydney Capital Showcase and Australia Biotech Invest, Melbourne.

Read More

BioDiem CEO appointed Chairman of Ausbiotech

December 5, 2014

BioDiem CEO appointed Chairman of Ausbiotech  

Read More